Back to Cell Types

PEO4Homo sapiens (Human)Cancer cell line

Also known as: PEO-4, PE04

🤖 AI SummaryBased on 13 publications

Quick Overview

Ovarian cancer cell line with BRCA2 mutation and platinum resistance

Detailed Summary

PEO4 is a human ovarian cancer cell line derived from a patient with high-grade serous ovarian carcinoma. It exhibits a BRCA2 mutation and demonstrates resistance to platinum-based chemotherapy. PEO4 is commonly used in research to study mechanisms of drug resistance and the role of BRCA2 in ovarian cancer progression. The cell line has been utilized in studies investigating the functional restoration of BRCA2 through secondary mutations and its implications for treatment response. PEO4 is also used to understand the genetic and molecular changes associated with platinum resistance in ovarian cancer.

Research Applications

Study of BRCA2 mutations and platinum resistanceInvestigation of drug resistance mechanismsAnalysis of genetic and molecular changes in ovarian cancerFunctional studies of BRCA2 restoration

Key Characteristics

BRCA2 mutationPlatinum resistanceHigh-grade serous ovarian carcinomaUsed in studies of drug resistance and BRCA2 function

Generated on 6/19/2025

Basic Information

Database ID	CVCL_2690
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age Category	Unknown
Sex	Female

Disease Information

Disease	Hereditary breast and ovarian cancer syndrome
Lineage	Ovary/Fallopian Tube
Subtype	Serous Ovarian Cancer
OncoTree Code	SOC

DepMap Information

Source Type	Sigma-Aldrich
Source ID	ACH-001632_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Gly244Asp (c.731G>A)	Unspecified	-	PubMed=28273451
MutationSimple	NF1	p.Arg160Trp (c.478A>T)	Homozygous	-	from parent cell line PEO4
MutationSimple	BRCA2	p.Tyr1655Tyr (c.4965C>T) (5193C>T)	Hemizygous	De novo mutation that cancels the c.4965C>G	PubMed=19654294

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

10,12

D13S317

10

D16S539

9

D18S51

16,17

D19S433

13,15

D21S11

30,32.2

D2S1338

20,21

D3S1358

16

D5S818

11,12

D7S820

10

D8S1179

13,14

FGA

20

Penta D

9,14

Penta E

11,12

TH01

9.3

TPOX

9,11

vWA

15,16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.

Wang P., Birrer M.J., Paulovich A.G.

Cell Rep. Med. 2:100471.1-100471.32(2021).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.

Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.

Nat. Commun. 7:12645.1-12645.14(2016).

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Noonan A.M., Annunziata C.M.

Gynecol. Oncol. 142:332-340(2016).

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

OncoImmunology 3:e954893.1-e954893.12(2014).

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mills G.B., Hennessy B.T.

Mol. Oncol. 7:567-579(2013).

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

Genomic complexity and AKT dependence in serous ovarian cancer.";

Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Cancer Discov. 2:56-67(2012).

The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.

Batty E.M., Pole J.C.M., Langdon S.P., Edwards P.A.W., Brenton J.D.

J. Pathol. 226:703-712(2012).

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.

Langdon S.P., Huntsman D.G., Brenton J.D.

Oncogene 29:4905-4913(2010).

Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.

Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T.

Cancer Res. 69:6381-6386(2009).

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.

Cancer Res. 57:850-856(1997).

Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines.

Mullen P., Ritchie A., Langdon S.P., Miller W.R.

Int. J. Cancer 67:816-820(1996).

Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient.

Adams D.J., Lewis A.D., Scott A.R.R., Smyth J.F.

Int. J. Cancer 39:695-702(1987).

Characterization and properties of nine human ovarian adenocarcinoma cell lines.

Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.

Cancer Res. 48:6166-6172(1988).

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Anderson M.E.

Proc. Natl. Acad. Sci. U.S.A. 89:3070-3074(1992).